Self-esteem is associated with premorbid adjustment and positive psychotic symptoms in early psychosis

<p>Abstract</p> <p>Background</p> <p>Low levels of self-esteem have been implicated as both a cause and a consequence of severe mental disorders. The main aims of the study were to examine whether premorbid adjustment has an impact on the subject's self-esteem, and whether lowered self-esteem contributes to the development of delusions and hallucinations.</p> <p>Method</p> <p>A total of 113 patients from the Thematically Organized Psychosis research study (TOP) were included at first treatment. The Positive and Negative Syndrome Scale (PANSS) was used to assess present symptoms. Premorbid adjustment was measured with the Premorbid Adjustment Scale (PAS) and self-esteem by the Rosenberg Self-Esteem Scale (RSES).</p> <p>Results</p> <p>Premorbid social adjustment was significantly related to lower self-esteem and explained a significant proportion of the variance in self-esteem. Self-esteem was significantly associated with the levels of persecutory delusions and hallucinations experienced by the patient and explained a significant proportion of the variance even after adjusting for premorbid functioning and depression.</p> <p>Conclusion</p> <p>There are reasons to suspect that premorbid functioning is an important aspect in the development of self- esteem, and, furthermore, that self-esteem is associated with the development of delusions and hallucinations.</p

Comment définir et diagnostiquer la dénutrition chez le sujet obèse ?

National audienceUndernutrition in the obese patient, like the non-obese patient, has numerous clinical consequences and leads to an increase in morbidity and mortality, but it is still underestimated. It is therefore imperative to prevent, detect and manage it as early as possible especially in patients at risk or weakened by a chronic disease. However, the definition and diagnostic criteria for undernutrition in non-obese adult subjects are flawed due to the clinical, morphological and biological characteristics associated with excessive adiposity. In an area where there is no consensus, the aim of this review is to highlight the difficulties in assessing undernutrition in this circumstance and to clarify the parameters of undernutrition assessment and their limits in the situation of obesity.La dénutrition chez le patient obèse, à l’instar du patient non obèse, expose à de nombreuses conséquences cliniques et aboutit à un accroissement de la morbi-mortalité mais reste fortement sous-estimée. Il est donc impératif de la prévenir, de la dépister et de la prendre en charge le plus tôt possible surtout chez les patients à risque ou fragilisés par une maladie chronique. Cependant, la définition et les critères de diagnostic de la dénutrition destinés aux sujets adultes non obèses sont mis en défaut en raison des particularités cliniques, morphologiques et biologiques liées à l’adiposité excessive. Dans un domaine où il n’existe pas de consensus, cette synthèse a pour objectif de souligner les difficultés d’appréciation de la dénutrition dans cette circonstance et d’apporter des éclaircissements sur les paramètres de l’évaluation de la dénutrition et leurs limites en situation d’obésité

Guidance on mucositis assessment from the MASCC Mucositis Study Group and ISOO: an international Delphi studyResearch in context

Summary: Background: Mucositis is a common and highly impactful side effect of conventional and emerging cancer therapy and thus the subject of intense investigation. Although common practice, mucositis assessment is heterogeneously adopted and poorly guided, impacting evidence synthesis and translation. The Multinational Association of Supportive Care in Cancer (MASCC) Mucositis Study Group (MSG) therefore aimed to establish expert recommendations for how existing mucositis assessment tools should be used, in clinical care and trials contexts, to improve the consistency of mucositis assessment. Methods: This study was conducted over two stages (January 2022–July 2023). The first phase involved a survey to MASCC-MSG members (January 2022–May 2022), capturing current practices, challenges and preferences. These then informed the second phase, in which a set of initial recommendations were prepared and refined using the Delphi method (February 2023–May 2023). Consensus was defined as agreement on a parameter by >80% of respondents. Findings: Seventy-two MASCC-MSG members completed the first phase of the study (37 females, 34 males, mainly oral care specialists). High variability was noted in the use of mucositis assessment tools, with a high reliance on clinician assessment compared to patient reported outcome measures (PROMs, 47% vs 3%, 37% used a combination). The World Health Organization (WHO) and Common Terminology Criteria for Adverse Events (CTCAE) scales were most commonly used to assess mucositis across multiple settings. Initial recommendations were reviewed by experienced MSG members and following two rounds of Delphi survey consensus was achieved in 91 of 100 recommendations. For example, in patients receiving chemotherapy, the recommended tool for clinician assessment in clinical practice is WHO for oral mucositis (89.5% consensus), and WHO or CTCAE for gastrointestinal mucositis (85.7% consensus). The recommended PROM in clinical trials is OMD/WQ for oral mucositis (93.3% consensus), and PRO-CTCAE for gastrointestinal mucositis (83.3% consensus). Interpretation: These new recommendations provide much needed guidance on mucositis assessment and may be applied in both clinical practice and research to streamline comparison and synthesis of global data sets, thus accelerating translation of new knowledge into clinical practice. Funding: No funding was received